Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: J Immunol. 2021 Jul 23;207(3):849–859. doi: 10.4049/jimmunol.2000708

Figure 4. PTPN22–mediated abrogation of proliferation requires APC activation.

Figure 4.

Proliferation was assessed for Tconv (A) and Tregs (B) overexpressing the LYP-620R variant, the LYP-620W risk variant, or eGFP transfected controls. Proliferation assessed by cell tracking dye dilution and was compared to internal mock control cells (GFP-). Three activation stimuli were compared: autologous antigen presenting cells (APC) along with soluble anti-CD3 and anti-CD28, surface-fixed anti-CD3/CD28 beads, and mitogenic compounds that bypass TCR signaling (PMA/Ionomycin). (Tconv donors n=6, Treg donors n=5, Two-way ANOVA using subject and treatment matching with Bonferroni posttest, *p<0.05, **p<0.01, ***p<0.001).